Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2018 call → NO我们只需要根据提供的文本判断管理层的描述是否体现了“同类业务规模逐步扩大”的现象。文本中,管理层讨论了VIVITROL、ARISTADA、ALKS 5461、3831等,但重点在于销售增长、市场扩张、政策影响等,没有明确提到“新订单/合同/项目规模比过去更大”的对比。例如,关于ARISTADA,提到“unit growth of 44%”和“two-month dose grew 26%”,但这是数量增长,不是单个交易规模扩大。关于VIVITROL,提到“unit growth of 18%”,也是数量。没有提到“平均订单规模上升”或“新客户初始规模更大”等。管理层提到“expanding our field and hospital-based sales force by approximately 50 sales representatives”,但这是销售团队扩张,不是交易规模。关于ALKS 5461和3831,是研发进展,不是商业交易。因此,没有证据表明管理层描述了“同类业务规模逐步扩大”的现象。答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.